Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development Service Platform
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon Support
IND 100 Publications
Feb 08,2021
3D011-08 from 3D Medicines was approved of conducting clinical trials
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
See More
3D011-08 from 3D Medicines was approved of conducting clinical trials
Feb 08,2021
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
See More
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Oct 31,2020
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.
See More
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
Jul 20,2020
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more
See More
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
Jun 04,2020
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Congratualtions to Medicilon's partner, Bio-Thera, on obtaining NMPA's approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of
See More
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
May 26,2020
Congratulations on the Successful Listing of Kintor Pharma
On May 22, 2020, Kintor Pharmaceutical Limited (stock code: 9939. HK) was officially listed on the Hong Kong Stock Exchange. We medicilon extend the congratulations and best wishes. Medicilon has joined hands with in multiple pharmaceutical development projects in recent years, including external preclinical pharmacokinetic studies and safety evaluation of the androgen receptor antagonist FrestatinRead more
See More
Congratulations on the Successful Listing of Kintor Pharma
Mar 15,2020
Medicilon assisted Zhejiang Bolaatu Medical Technology Co., Ltd on PA1010 tablets with implied permission for clinical trials
On March 10, 2020, PA1010 tablets, which are independently developed by Zhejiang Bolaatu Medical Technology Co., Ltd, obtained the implied license for NMPA clinical trials. This is the first new drug declared by Bolaatu.  PA1010 is a new class I drug for chronic hepatitis B (CHB). Zhejiang Bolaatu is a new drug research and developmentRead more
See More
Medicilon assisted Zhejiang Bolaatu Medical Technology Co., Ltd on PA1010 tablets with implied permission for clinical trials
Feb 26,2020
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH).  IPAH is a progressive disease that affects the precapillary pulmonary vasculature.  IPAH is a rare and fatal disease which has a high mortality rate. During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and developmentRead more
See More
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Dec 27,2019
Medicilon Assists Neupharma's RX108 to Enter Phase I Clinical Trials
​Recently, Suzhou Neupharma, an important partner of Shanghai Medicilon, announced that RX208 China phase I clinical research has completed the administration of the first patient in Shanghai Dongfang Hispital.
See More
Medicilon Assists Neupharma's RX108 to Enter Phase I Clinical Trials
Dec 19,2019
Medicilon assists Cgenetech to accelerate the development of new anti-diabetic drugs
On December 7, 2019, the 2019 annual meeting of the Biomedical Branch of the Shanghai European and American Alumni Association was held in Shanghai Pudong
See More
Medicilon assists Cgenetech to accelerate the development of new anti-diabetic drugs
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->